Format

Send to

Choose Destination
Pharmacogenomics. 2016 Nov;17(16):1741-1747. doi: 10.2217/pgs-2016-0153. Epub 2016 Oct 28.

Pharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America.

Author information

1
RIBEF, Ibero-American Network of Pharmacogenetics & Pharmacogenomics, Mérida, Badajoz, Spain.
2
Instituto Politéctico Nacional-CIIDIR, Unidad Durango, Academia de Genómica, Durango, Mexico.
3
Colegio de Ciencias de la Salud, Universidad San Francisco de Quito, Quito, Ecuador.
4
Comité de Ética en Seres Humanos, Universidad San Francisco de Quito, Quito, Ecuador.
5
Facultad de Medicina, Universidad de las Américas, Quito, Ecuador.
6
Universidad Nacional Autónoma de Nicaragua, León, Facultad de Medicina, Nicaragua.
7
Facultad de Química, Universidad Nacional Autónoma de México, México.
8
Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana, Xochimilco, México.
9
Centro para el Control Estatal de Medicamentos, La Habana, Cuba.
10
Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina.
11
Facultad de Ciencias Médicas, Universidad Estatal de Guayaquil, Guayaquil, Ecuador.
12
CICAB Clinical Research Centre, Extremadura University Hospital & Medical School, Badajoz, Spain.
13
Genetics Section, Universidad de Costa Rica, San José, Costa Rica.
14
Universidade Federal de Minas Gerais, Instituto de Ciencias Biológicas, Departamento de Biologia Geral, Belo Horizonte, Brazil.

Abstract

Congress of Pharmacogenetics and Personalized Medicine. Ethnicity, clinical implementation and regulatory environment (MESTIFAR 2016 Quito) Quito, Ecuador, 19-21 May 2016. The Ibero-American Network of Pharmacogenetics and Pharmacogenomics (RIBEF) was created in 2006 with the main aim of promoting personalized medicine and collaborative pharmacogenetics research in Spanish- and Portuguese-speaking countries in America and the Iberian Peninsula. The final goal of this initiative was the inclusion of Latin American populations that may benefit from the implementation of personalized medicine in drug therapy. Several initiatives have been promoted including the MESTIFAR project, which aimed to analyze the ethnicity, genotype and/or metabolic phenotype in Ibero-American populations. To date, 6060 healthy volunteers have been analyzed; among them, 2571 were admixed, 1824 were Caucasians, 1395 were Native Americans, 174 were Jews and 96 were Afro-descendants. Due to the large genetic variability within Latin Americans, ethnicity may be a relevant factor for the clinical implementation of personalized medicine. Moreover, the present status of clinical implementation and the future perspectives of pharmacogenetics, pharmacovigilance and clinical trials for drug regulation in Latin America compared with the EMA-Pharmacogenomics Working Party and the US FDA initiatives were analyzed.

KEYWORDS:

Latin American populations; clinical trials; metabolic genotypes; metabolic phenotypes; native populations; pharmacogenetics; pharmacovigilance

PMID:
27790935
DOI:
10.2217/pgs-2016-0153

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center